269787 SEARCH REQUEST FORM LB

Requester's Full Name: Cecilia Tajsle Examiner #: _____ Date: 8-19-08
Art Unit: 1624 Phone Number: 2-9931 Serial Number: 10538126
Location (Bldg/Room#): REM 5A28 (Mailbox #): 5018 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: See Bib Data Sheet

Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

See claims attached. Please do structure search and inventor name(s) search. Display results to show identification of source, and RN#, compound name & structure of identified compounds. Search compounds of Formula I. See previous search

RECEIVED AUG 19 2008 OIPE/IAP

Please call with any questions

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: _____
Searcher Prep & Review Time: _____
Online Time: _____

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
_____ Structure (#)
_____ Bibliographic
_____ Litigation
_____ Fulltext
_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet

In-house sequence systems

_____ Commercial _____ Oligomer _____ Specific
_____ Interference _____ SPDI _____ Encode/Translate
_____ Other (specify)

```
=> fil reg; d stat que l17; fil zcapl; d que nos l19; fil marpat; d que nos l22;
dup rem l19,l22
FILE 'REGISTRY' ENTERED AT 09:34:55 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2008  HIGHEST RN 1042061-07-3
DICTIONARY FILE UPDATES:  19 AUG 2008  HIGHEST RN 1042061-07-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html


L14             STR
```




```
VAR G1=NO2/CN/58/18
VAR G2=20/22/24
VAR G3=11/12/13
VAR G4=50/51/53
VAR G5=35/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  18 19 58
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

```
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  48

STEREO ATTRIBUTES: NONE
L17         110 SEA FILE=REGISTRY SSS FUL L14

100.0% PROCESSED   47108 ITERATIONS                          110 ANSWERS
SEARCH TIME: 00.00.01



FILE 'ZCAPLUS' ENTERED AT 09:34:56 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 20 Aug 2008  VOL 149 ISS 8
FILE LAST UPDATED: 19 Aug 2008  (20080819/ED)

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE


L14             STR
L17         110 SEA FILE=REGISTRY SSS FUL L14
L19           3 SEA FILE=ZCAPLUS ABB=ON  L17



FILE 'MARPAT' ENTERED AT 09:34:56 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 6 (20080815/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20080154069 26 JUN 2008
```

```
DE 102007060672 26 JUN 2008
EP      1939177 02 JUL 2008
JP   2008153047 03 JUL 2008
WO   2008083542 17 JUL 2008
GB      2444641 11 JUN 2008
FR      2910473 27 JUN 2008
RU      2327710 27 JUN 2008
CA      2615024 14 JUN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
have increased from 100,000 to 200,000 for both on-line and batch
searches.  For more information on MARPAT search limits, type HELP
SLIMITS at an arrow prompt.


L14             STR
L22           9 SEA FILE=MARPAT SSS FUL L14



FILE 'ZCAPLUS' ENTERED AT 09:34:56 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MARPAT' ENTERED AT 09:34:56 ON 20 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)
PROCESSING COMPLETED FOR L19
PROCESSING COMPLETED FOR L22
L23          10 DUP REM L19 L22 (2 DUPLICATES REMOVED)
                ANSWERS '1-3' FROM FILE ZCAPLUS
                ANSWERS '4-10' FROM FILE MARPAT

=> d ibib abs hitstr 1-3; d ibib abs qhit 4-10; fil hom

L23  ANSWER 1 OF 10  ZCAPLUS  COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2005:1329720  ZCAPLUS  Full-text
DOCUMENT NUMBER:          144:69841
TITLE:                    Preparation of 3-phenyltetrahydrocinnolin-5-ol
                          derivatives as antitumor agents
INVENTOR(S):              Sato, Yoshitaka; Suzuki, Yoshikazu; Yamamoto,
                          Keiichiro; Kuroiwa, Shunsuke; Maruyama, Sakiko
PATENT ASSIGNEE(S):       Nippon Kayaku Kabushiki Kaisha, Japan
SOURCE:                   PCT Int. Appl., 41 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 2005121105         A1    20051222    WO 2005-JP10494        20050608
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
```

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005252074	A1	20051222	AU 2005-252074	20050608
CA 2568301	A1	20051222	CA 2005-2568301	20050608
EP 1757592	A1	20070228	EP 2005-748792	20050608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1964953	A	20070516	CN 2005-80018872	20050608
BR 2005011879	A	20080115	BR 2005-11879	20050608
KR 2007029735	A	20070314	KR 2006-725395	20061201
US 20080039468	A1	20080214	US 2007-597232	20070126
PRIORITY APPLN. INFO.:			JP 2004-171426 A	20040609
			WO 2005-JP10494 W	20050608

OTHER SOURCE(S): MARPAT 144:69841

GI



I



II

AB Title compds. I [Z = M-, L(L')N-, A(B)CH-; M = alkoxy, alkylamino, optionally substituted alkyl with saturated heterocycle; L, L' = hydroxy, alkoxy, carboxy, etc.; A = H, hydroxy, alkyl; B = substituted alkyl, alkoxy, carboxy, etc.; X = alkyl, alkoxycarbonyl, acylamino, etc.; X' = alkyl, alkoxycarbonyl, acylamino, etc.; Y, Y' = H, alkyl] were prepared For example, EDC mediated acylation of 7-methyl-3-(3-trifluoromethylphenyl)- 5,6,7,8-tetrahydrocinnolin-5-ol, e.g., prepared from 3'- trifluoromethylacetophenone in 5 steps, with ethoxyacetic acid afforded compound II in 98.8% yield. In antitumor assays in vitro, the IC50 value of compound II was 0.135 μg/mL. Compds. I are claimed useful for the treatment of tumor.

IT 871840-18-5P 871840-22-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 3-phenyltetrahydrocinnolin-5-ol derivs. as antitumor agents)

RN 871840-18-5 ZCAPLUS

CN Acetic acid, 2-(carboxymethoxy)-, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



RN 871840-22-1 ZCAPLUS

CN Butanedioic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



IT 871840-17-4P 871840-19-6P 871840-20-9P
871840-21-0P 871840-23-2P 871840-24-3P
871840-25-4P 871840-26-5P 871840-27-6P
871840-28-7P 871840-30-1P 871840-32-3P
871840-33-4P 871840-35-6P 871840-37-8P
871840-39-0P 871840-40-3P 871840-42-5P
871840-44-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-phenyltetrahydrocinnolin-5-ol derivs. as antitumor agents)

RN 871840-17-4 ZCAPLUS

CN Acetic acid, 2-ethoxy-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 871840-19-6 ZCAPLUS

CN Acetic acid, 2-[2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethoxy]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl

ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 871840-20-9 ZCAPLUS
CN Acetic acid, 2-[2-oxo-2-[(3-pyridinylmethyl)amino]ethoxy]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 871840-21-0 ZCAPLUS
CN Acetic acid, 2-[2-oxo-2-[(4-pyridinylmethyl)amino]ethoxy]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 871840-23-2 ZCAPLUS
CN Pentanedioic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



RN 871840-24-3 ZCAPLUS
CN Butanedioic acid, 2-hydroxy-, 4-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



RN 871840-25-4 ZCAPLUS
CN Butanoic acid, 4-(dimethylamino)-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 871840-26-5 ZCAPLUS
CN Propanedioic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester, hydrochloride (1:1) (CA INDEX NAME)



RN 871840-27-6 ZCAPLUS
CN Butanoic acid, 4-[[2-(4-morpholinyl)ethyl]amino]-4-oxo-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 871840-28-7 ZCAPLUS
CN Butanoic acid, 4-oxo-4-[(3-pyridinylmethyl)amino]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 871840-30-1 ZCAPLUS
CN Butanoic acid, 4-oxo-4-[(4-pyridinylmethyl)amino]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 871840-32-3 ZCAPLUS
CN Butanedioic acid, 1-methyl 4-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



RN 871840-33-4 ZCAPLUS
CN Butanedioic acid, 1-ethyl 4-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)



RN 871840-35-6 ZCAPLUS
CN Carbonic acid, 2-methoxyethyl 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (9CI) (CA INDEX NAME)



RN 871840-37-8 ZCAPLUS
CN Carbonic acid, 2-(4-morpholinyl)ethyl 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (9CI) (CA INDEX NAME)



RN 871840-39-0 ZCAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 871840-40-3 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-(4-morpholinyl)-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 871840-42-5 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-methyl-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 871840-44-7 ZCAPLUS
CN 4-Morpholinecarboxylic acid, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, hydrochloride (1:1) (CA INDEX NAME)



IT 708984-57-0P, 7-Methyl-3-(3-trifluoromethylphenyl)-7,8-dihydro-6H-cinnolin-5-one 708984-65-0P 871840-48-1P 871840-50-5P 871840-52-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-phenyltetrahydrocinnolin-5-ol derivs. as antitumor agents)
RN 708984-57-0 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-65-0 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 871840-48-1 ZCAPLUS
CN Carbonic acid, phenyl 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (9CI) (CA INDEX NAME)



RN 871840-50-5 ZCAPLUS
CN Carbonic acid, 2-chloroethyl 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (9CI) (CA INDEX NAME)



RN 871840-52-7 ZCAPLUS
CN 1,3-Dioxolane-4-acetic acid, 2,2-dimethyl-5-oxo-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:515490 ZCAPLUS Full-text
DOCUMENT NUMBER: 141:71553
TITLE: Preparation of 3-phenylcinnoline homologues as antitumor agents
INVENTOR(S): Kuroiwa, Shunsuke; Odanaka, Junko; Maruyama, Sakiko; Sato, Yoshitaka; Tomura, Arihiro; Sato, Hiroshi; Suzuki, Yoshikazu
PATENT ASSIGNEE(S): Nippon Kayaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052866	A1	20040624	WO 2003-JP15767	20031210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508010	A1	20040624	CA 2003-2508010	20031210
AU 2003289002	A1	20040630	AU 2003-289002	20031210
EP 1571148	A1	20050907	EP 2003-778763	20031210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017119	A	20051025	BR 2003-17119	20031210
CN 1735600	A	20060215	CN 2003-80108285	20031210
RU 2324683	C2	20080520	RU 2005-121559	20031210
US 20060058305	A1	20060316	US 2005-538126	20050606
PRIORITY APPLN. INFO.:			JP 2002-357556 A	20021210
			JP 2003-166082 A	20030611
			JP 2003-183766 A	20030627

WO 2003-JP15767 W 20031210

OTHER SOURCE(S): MARPAT 141:71553

GI



I

AB Title compds. I [A = O-Y; Y = H, (un)substituted alkyl with Ph, etc.; B = H, alkyl, further details on A, B are given; L = N-W, W-C-W'; W, W' = (un)substituted alkyl, Ph, carboxyl, etc.; X = alkyl, alkoxycarbonyl, acylamino, etc.; X' = alkyl, alkoxycarbonyl, acylamino, etc.; m, q = 0-3; n, n' = 0, 1] and their physiol. acceptable salt were prepared In antitumor activity assays (in vitro) against breast cancer cell CF-7, compds. I showed IC50 values ranging from 0.0388 to 3.5700 μg/mL, e.g., the IC50 value of compound I [A and B = carbonyl; L = PhCH; X = 3-CF3-Ph; X' = H; m = q = n = n' = 0] was 0.0388 μg/mL. Compds. I are claimed useful as antitumor, cytostatic agents.

IT 708983-93-1P 708983-95-3P, 5-Hydroxy-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnoline-7-carboxylic acid ethyl ester 708983-98-6P 708984-00-3P 708984-07-0P, 3-(3-Cyanophenyl)-7-methyl-7,8-dihydro-6H-cinnolin-5-one 708984-20-7P 708984-23-0P 708984-25-2P 708984-27-4P 708984-31-0P 708984-33-2P 708984-35-4P 708984-37-6P 708984-39-8P 708984-41-2P 708984-44-5P 708984-46-7P 708984-47-8P 708984-49-0P 708984-53-6P 708984-57-0P, 7-Methyl-3-(3-trifluoromethylphenyl)-7,8-dihydro-6H-cinnolin-5-one 708984-61-6P, 7-Methyl-3-(3-trifluoromethylphenyl)cinnolin-5-ol 709640-62-0P 709640-63-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-phenylcinnoline homolog as antitumor agents)

RN 708983-93-1 ZCAPLUS

CN 7-Cinnolinecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-3-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 708983-95-3 ZCAPLUS

CN 7-Cinnolinecarboxylic acid, 5,6,7,8-tetrahydro-5-hydroxy-3-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 708983-98-6 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-00-3 ZCAPLUS
CN 1,2-Pyrrolidinedicarboxylic acid, 1-(1,1-dimethylethyl) 2-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-07-0 ZCAPLUS
CN Benzonitrile, 3-(5,6,7,8-tetrahydro-7-methyl-5-oxo-3-cinnolinyl)- (CA INDEX NAME)



RN 708984-20-7 ZCAPLUS
CN 5(6H)-Cinnolinone, 3-[2-fluoro-5-(trifluoromethyl)phenyl]-7,8-dihydro-7-

methyl- (CA INDEX NAME)



RN 708984-23-0 ZCAPLUS
CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-25-2 ZCAPLUS
CN L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-27-4 ZCAPLUS
CN L-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-(1,1-dimethylethyl) 4-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-31-0 ZCAPLUS
CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 1-(1,1-dimethylethyl) 5-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-33-2 ZCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, (5R,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-35-4 ZCAPLUS
CN L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-37-6 ZCAPLUS
CN L-Lysine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-39-8 ZCAPLUS
CN L-Methionine, N-[(1,1-dimethylethoxy)carbonyl]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-41-2 ZCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-44-5 ZCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (5S,7S)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-46-7 ZCAPLUS
CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, (5S,7S)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-47-8 ZCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (5R,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-49-0 ZCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (5S,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-53-6 ZCAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, (5R,7S)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-57-0 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-61-6 ZCAPLUS
CN 5-Cinnolinol, 7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 709640-62-0 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5S,7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 709640-63-1 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 708983-92-0P, 7-Phenyl-3-(3-trifluoromethylphenyl)-7,8-dihydro-6H-cinnolin-5-one 708983-96-4P, 5-Hydroxy-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnoline-7-carboxylic acid 708983-97-5P 708983-99-7P 708984-01-4P 708984-02-5P 708984-03-6P 708984-04-7P 708984-05-8P 708984-06-9P, 7-Hydroxymethyl-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnolin-5-ol 708984-08-1P 708984-10-5P, 3-(3-Trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnolin-5-ol 708984-11-6P, 3-(3-Bromophenyl)-7-methyl-7,8-dihydro-6H-cinnolin-5-one 708984-12-7P, 7-Methyl-3-(3-nitrophenyl)-7,8-dihydro-6H-cinnolin-5-one 708984-16-1P, 3-(3-Fluorophenyl)-7-methyl-7,8-dihydro-6H-cinnolin-5-one 708984-19-4P 708984-21-8P 708984-22-9P, 5,7-Dimethyl-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnolin-5-ol 708984-24-1P 708984-26-3P 708984-28-5P 708984-29-6P 708984-30-9P 708984-32-1P 708984-34-3P 708984-36-5P 708984-38-7P 708984-40-1P 708984-42-3P 708984-43-4P 708984-45-6P 708984-48-9P 708984-51-4P, (5S,7R)-7-Methyl-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnolin-5-ol 708984-52-5P 708984-54-7P, (5R,7S)-7-Methyl-3-(3-trifluoromethylphenyl)-5,6,7,8-tetrahydrocinnolin-5-ol 708984-55-8P 708984-58-1P 708984-59-2P, 3-(3-Trifluoromethylphenyl)-7,8-dihydro-6H-cinnolin-5-one 708984-62-7P, 5-Methoxy-7-methyl-3-(3-trifluoromethylphenyl)cinnoline 708984-63-8P, 5-Acetyloxy-7-methyl-3-(3-trifluoromethylphenyl)cinnoline 708984-64-9P, 5-Benzyloxy-7-methyl-3-(3-trifluoromethylphenyl)cinnoline 708984-65-0P 708984-66-1P 708984-67-2P 708984-68-3P 708984-69-4P 708984-70-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-phenylcinnoline homolog as antitumor agents)

RN 708983-92-0 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-phenyl-3-[3-(trifluoromethyl)phenyl]-

(CA INDEX NAME)



RN 708983-96-4 ZCAPLUS
CN 7-Cinnolinecarboxylic acid, 5,6,7,8-tetrahydro-5-hydroxy-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708983-97-5 ZCAPLUS
CN 7-Cinnolinecarboxylic acid, 5,6,7,8-tetrahydro-5-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708983-99-7 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-01-4 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7R)-rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



RN 708984-02-5 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7R)-rel-(+)- (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



RN 708984-03-6 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 5-acetate, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-04-7 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 1-oxide, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-05-8 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 1-oxide (CA INDEX NAME)



RN 708984-06-9 ZCAPLUS
CN 7-Cinnolinemethanol, 5,6,7,8-tetrahydro-5-hydroxy-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-08-1 ZCAPLUS
CN Benzonitrile, 3-[(5R,7R)-5,6,7,8-tetrahydro-5-hydroxy-7-methyl-3-cinnolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-10-5 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-11-6 ZCAPLUS
CN 5(6H)-Cinnolinone, 3-(3-bromophenyl)-7,8-dihydro-7-methyl- (CA INDEX NAME)



RN 708984-12-7 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-methyl-3-(3-nitrophenyl)- (CA INDEX NAME)



RN 708984-16-1 ZCAPLUS
CN 5(6H)-Cinnolinone, 3-(3-fluorophenyl)-7,8-dihydro-7-methyl- (CA INDEX NAME)



RN 708984-19-4 ZCAPLUS
CN 7-Cinnolinemethanol, 5,6,7,8-tetrahydro-5-hydroxy-α,α-dimethyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-21-8 ZCAPLUS
CN 5-Cinnolinol, 3-[2-fluoro-5-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)



RN 708984-22-9 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-5,7-dimethyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-24-1 ZCAPLUS
CN L-Alanine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-26-3 ZCAPLUS
CN L-Aspartic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-28-5 ZCAPLUS

CN L-Aspartic acid, 4-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-29-6 ZCAPLUS
CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 5-(1,1-dimethylethyl) 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-30-9 ZCAPLUS
CN L-Glutamic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-32-1 ZCAPLUS
CN L-Glutamic acid, 5-[5,6,7,8-tetrahydro-7-methyl-3-[3-

(trifluoromethyl)phenyl]-5-cinnolinyl] ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-34-3 ZCAPLUS
CN Glycine, (5R,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl

RN 708984-36-5 ZCAPLUS
CN L-Leucine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-38-7 ZCAPLUS
CN L-Lysine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-

cinnolinyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HCl

RN 708984-40-1 ZCAPLUS
CN L-Methionine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-42-3 ZCAPLUS
CN L-Phenylalanine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-43-4 ZCAPLUS
CN L-Proline, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 708984-45-6 ZCAPLUS
CN L-Valine, (5S,7S)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 708984-48-9 ZCAPLUS
CN L-Valine, (5R,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

RN 708984-51-4 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-,

(5S,7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-52-5 ZCAPLUS
CN L-Valine, (5S,7R)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 708984-54-7 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-55-8 ZCAPLUS
CN L-Valine, (5R,7S)-5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● 2 HCl

RN 708984-58-1 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, hydrazone (CA INDEX NAME)



RN 708984-59-2 ZCAPLUS
CN 5(6H)-Cinnolinone, 7,8-dihydro-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-62-7 ZCAPLUS
CN Cinnoline, 5-methoxy-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-63-8 ZCAPLUS
CN 5-Cinnolinol, 7-methyl-3-[3-(trifluoromethyl)phenyl]-, 5-acetate (CA INDEX NAME)



RN 708984-64-9 ZCAPLUS
CN Cinnoline, 7-methyl-5-(phenylmethoxy)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-65-0 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 708984-66-1 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 1-oxide (CA INDEX NAME)



RN 708984-67-2 ZCAPLUS
CN Glycine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)



RN 708984-68-3 ZCAPLUS
CN L-Alanine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-69-4 ZCAPLUS
CN L-Valine, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 708984-70-7 ZCAPLUS
CN L-Glutamic acid, 1-[5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-5-cinnolinyl] ester (CA INDEX NAME)

Absolute stereochemistry.



L23 ANSWER 3 OF 10 ZCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:915946 ZCAPLUS Full-text
TITLE: Preparation of trifluoromethylphenyltetrahydrocinnolin e derivatives as antitumor agents
INVENTOR(S): Watanabe, Takahiro; Sato, Yoshitaka; Saito, Seiichi
PATENT ASSIGNEE(S): Nippon Kayaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 40pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008090884	A1	20080731	WO 2008-JP50809	20080122

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2007-12118 A 20070123
GI



I



II

AB Title compds. I [X1-X5 = H or hydroxy; at least one of X1-X5 is hydroxy; X6 = H or hydroxy] or their physiol. acceptable salts were prepared For example, reaction of cis-7-methyl-1-oxy-3-(3-trifluoromethylphenyl)- 5,6,7,8-tetrahydrocinnolin-5-ol with trifluoroacetic anhydride followed by treatment with K2CO3 in methanol and silica-gel separation afforded two isomers of

compound II. One isomer of compound II showed the IC50 value of 0.099 (μg/mL) against MCF-7 (breast cancer cell).

IT 708983-98-6 708984-04-7 708984-65-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of trifluoromethylphenyltetrahydrocinnoline derivs. as antitumor agents)

RN 708983-98-6 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-04-7 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 1-oxide, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 708984-65-0 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 708984-03-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of trifluoromethylphenyltetrahydrocinnoline derivs. as antitumor agents)

RN 708984-03-6 ZCAPLUS
CN 5-Cinnolinol, 5,6,7,8-tetrahydro-7-methyl-3-[3-(trifluoromethyl)phenyl]-, 5-acetate, (5R,7R)-rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 147:301163 MARPAT Full-text
TITLE: Preparation of novel acetyl-CoA carboxylase (ACC) inhibitors, particularly thiazole derivatives, and their use for treating diabetes, obesity and metabolic syndrome
INVENTOR(S): Gu, Yu Gui; Xu, Xiangdong; Weitzberg, Moshe; Sham, Hing
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007095603	A2	20070823	WO 2007-US62181	20070215
WO 2007095603	A3	20080313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070219251	A1	20070920	US 2007-675406	20070215

PRIORITY APPLN. INFO.: US 2006-773514P 20060215
OTHER SOURCE(S): CASREACT 147:301163
GI



II

AB The invention is related to compds. Ar3-Y-Ar1-Ar2 [I; Y = CO, O, NH, etc.; Ar1 = Ph, monocyclic 5-6 membered heteroaryl; Ar3 = substituted Ph, monocyclic heteroaryl; Ar2 = substituted Ph, pyridinyl, indanyl, etc.; and their pharmaceutically acceptable salts, prodrugs, salts of prodrugs, and their combinations], (e.g., II), which inhibit acetyl-CoA carboxylase (no data). Thus, a multi-step synthesis from 5-bromoindan-1-ol was given for thiazole II. I are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans (no data).

MSTR 1



G3 = phenylene (opt. substd. by G34)
G4 = 14



G10 = OH
G11 = 105-3 113-15



G12 = N / CH
G18 = (1-2) CH2
G34 = F
Patent location: claim 1
Note: substitution is restricted
Note: additional substitution also claimed
Note: or pharmaceutically acceptable salts, prodrugs, or combinations

L23 ANSWER 5 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 143:266921 MARPAT Full-text
TITLE: Preparation of novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
INVENTOR(S): Makovec, Francesco; Giordani, Antonio; Artusi,

Roberto; Mandelli, Stefano; Verpilio, Ilario; Zanzola, Simona; Rovati, Lucio Claudio
PATENT ASSIGNEE(S): Rottapharm S.P.A., Italy
SOURCE: Eur. Pat. Appl., 53 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571142	A1	20050907	EP 2005-101498	20050228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CA 2498644	A1	20050901	CA 2005-2498644	20050228
AU 2005200915	A1	20050915	AU 2005-200915	20050228
US 20050197331	A1	20050908	US 2005-68347	20050301
JP 2005247848	A	20050915	JP 2005-56076	20050301

PRIORITY APPLN. INFO.: IT 2004-TO125 20040301
OTHER SOURCE(S): CASREACT 143:266921
GI



I

AB Heterocyclic amidines are claimed with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I, G1 and G2 = H, halogen, OH, C1-C4 alkoxy, C1-C4 alkyl, and an amidino substituent, provided that only one of the two substituents G1 or G2 is an amidino substituent; W, Y and X combine to form 9- or 10-membered bicyclic heteroarom. derivs. containing up to 2 hetero atoms in the same ring; Z = aryl or heteroaryl group, a linear or branched C1-C6 alkyl or alkenyl chain, a C1-C4 alkyl-aryl group or a C1-C4 alkyl-heteroaryl group; and R3 and R4 = H, halogen, OH, C1-C4 alkoxy, C1-C4 alkenyl, or C1-C4 alkyl). Use of the compds., pharmaceutical compns. containing the compds., and a process for preparing them are also claimed.

MSTR 1



G3 = OH
G4 = 21-3 20-6 24-15



G5 = Ph (opt. substd. by 1 or more G7)
G7 = NO2
G9 = 26 / N



Patent location: claim 1
Note: substitution is restricted
Note: or pharmaceutically acceptable salts
Note: also incorporates claim 23

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 141:7138 MARPAT Full-text
TITLE: Preparation of bicyclic-substituted amines as histamine-3 receptor ligands
INVENTOR(S): Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-Jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-Yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-Ming; Sharma, Padam N.; Bennani, Youssef L.; Curtis, Michael P.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 229 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043458	A1	20040527	WO 2003-US35365	20031105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040092521	A1	20040513	US 2002-292422	20021112
US 20040152704	A1	20040805	US 2003-689735	20031022
US 7153889	B2	20061226		
CA 2505427	A1	20040527	CA 2003-2505427	20031105
AU 2003291329	A1	20040603	AU 2003-291329	20031105

EP 1569637 A1 20050907 EP 2003-768721 20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006514926 T 20060518 JP 2004-551799 20031105
MX 2005PA05116 A 20050701 MX 2005-PA5116 20050512
US 20060194798 A1 20060831 US 2006-418699 20060505
PRIORITY APPLN. INFO.: US 2002-292422 20021112
US 2002-425376P 20021112
US 2003-689735 20031022
WO 2003-US35365 20031105

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Y, and B = independently CH, CF, or N; X, A, Z, and C = independently C or N; one of R1 and R2 = halo, CN, aryl, aryloxy, etc.; the other of R1 and R2 = H, cyclo/alkyl, thio/alkoxy, aryl, halo, CN, provided that R2 is absent when C = N; R3 = H, alkyl, alkoxy, absent, etc.; R = absent, H, halo, Me, alkoxy, or CN; R6 = absent, H, alkyl, thio/alkoxy, halo, OH, CN; R4 and R5 = independently alkyl, haloalkyl, hydroxyalkyl, or NR4R5 = (un)1-pyrrolidinyl, 1-piperidinyl, 1-morpholinyl, etc.; L = (un)substituted alkylene or -alkylene-O-; their pharmaceutically acceptable salts, esters, amides, or prodrugs] were prepared as histamine-3 receptor ligands. For example, quinoxaline II was prepared in 6 steps via cyclocondensation of benzenediamine III with glyoxal in EtOH, followed by reaction with oxo(phenyl)acetaldehyde. Selected I showed binding affinities of 0.12 to 20 nM towards histamine-3 receptors in rats. I are useful for the treatment of memory disorder, cognition disorder, obesity, etc. (no data).

MSTR 1C



G1 = N
G3 = 21



G4 = 23



G5 = N
G7 = 1-28 8-13



G14 = Ph (opt. substd. by G37)
G20 = alkoxy <containing 1-10 C>
G35 = 252



G37 = CN
Patent location: claim 1
Note: substitution is restricted
Note: or pharmaceutically acceptable salts, esters, amides, or prodrugs

L23 ANSWER 7 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:406732 MARPAT Full-text
TITLE: Preparation of pyrrolidine derivatives as histamine-3 receptor ligands
INVENTOR(S): Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-ming; Sharma, Padam N.; Bennani, Youssef L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 55 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040092521	A1	20040513	US 2002-292422	20021112
CA 2505427	A1	20040527	CA 2003-2505427	20031105
WO 2004043458	A1	20040527	WO 2003-US35365	20031105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003291329	A1	20040603	AU 2003-291329	20031105
EP 1569637	A1	20050907	EP 2003-768721	20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514926	T	20060518	JP 2004-551799	20031105

MX 2005PA05116 A 20050701 MX 2005-PA5116 20050512
PRIORITY APPLN. INFO.: US 2002-292422 20021112
US 2002-425376P 20021112
US 2003-689735 20031022
WO 2003-US35365 20031105

GI



I

II

AB The title compds. I [wherein X, Y, and Y' = independently CH, CF, or N; X', Z, and Z' = independently C or N; R1 and R2 = independently halo, CN, H, alkyl, alkoxy, etc.; R3 = H, alkyl, alkoxy, absent, etc.; R3a = absent, H, halo, Me, alkoxy, or CN; R4 and R5 = independently alkyl, haloalkyl, hydroxyalkyl, etc.; L = (un)substituted alkylene or -alkylene-O-] or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof are prepared as histamine-3 receptor ligands. For example, the compound II was prepared in a multi-step synthesis. Some of compds. I showed binding affinities of 0.12 to 20 nM towards histamine-3 receptors in rat. I are useful for the treatment of memory disorder, cognition disorder, obesity, etc. (no data).

MSTR 1C



G1 = N / 11



G3 = 21



G4 = 23



G5 = N
G7 = 1-28 8-13



G14 = Ph (opt. substd. by G36)
G20 = alkoxy <containing 1-10 C>
G36 = CN
Patent location: claim 1
Note: substitution is restricted
Note: or pharmaceutically acceptable salts, esters, amides, or prodrugs

L23 ANSWER 8 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 137:140513 MARPAT Full-text
TITLE: Preparation of triaryl compounds as LDL receptor gene expression potentiating agents
INVENTOR(S): Ueno, Yoshihide; Umezome, Takashi; Asano, Shigehiro
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060876	A1	20020808	WO 2002-JP625	20020129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2002226464	A	20020814	JP 2001-22393	20010130
AU 2002226751	A1	20020812	AU 2002-226751	20020129
PRIORITY APPLN. INFO.:			JP 2001-22393	20010130
			WO 2002-JP625	20020129

GI



AB The title compds. I [a, b and c independently represent each CH or N; R1s independently represent each hydroxy, halogeno, etc.; m is from 0 to 3; D represents 1,3-phenylenediyl, etc.; Y represents an optionally represented benzene ring or a heterocycle; and Z represents CONR2S(O)nR3, etc. (wherein n is 1 or 2; R2 represents H or optionally substituted alkyl; and R3 represents optionally substituted alkyl, Ph, etc.)], useful for the treatment of hyperlipidemia, are prepared In an in vitro test using HepG2 cells, N-acetyl-3'-(2-quinolyl)-1,1'-biphenyl-4-sulfonamide at 0.15 μM showed LDL receptor gene expression potentiating activity.

MSTR 1



G1 = CH / N
G2 = OH
G12 = 66-9 68-38



G14 = 84



G16 = CH
G27 = F
Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 130:52428 MARPAT Full-text
TITLE: Process for the preparation of 4-cyanocinnoline derivatives
INVENTOR(S): Yoshida, Zenichi; Matsubara, Yoshio
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10310579	A	19981124	JP 1998-58674	19980310

PRIORITY APPLN. INFO.: JP 1997-56051 19970311
OTHER SOURCE(S): CASREACT 130:52428
GI



I



II

AB The title compds. (I; X = C1-10 alkyl, C7-20 aralkyl, C1-10 alkoxycarbonyl, OH, etc.; Y = halo, C1-10 alkyl, lower alkoxy, etc.; n = 0-4) are prepared by the reaction of compds. (II; X, Y, n = same as above; R1 = Me) with tetracyanoethylene in the presence of copper catalysts and cyclization. I, useful as intermediate in the production of drugs and pesticides, are prepared in an industrial manner efficiently and economically. Thus, II (X = C6H5, R1 = Me, Yn = H) was refluxed with tetracyanoethylene in MeCN to give 56% I (X = C6H5, Yn = H).

MSTR 1



G1 = Ph (opt. substd. by 1 or more G2)
G2 = NO2
G5 = loweralkoxy
Patent location: claim 1

L23 ANSWER 10 OF 10 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 127:17703 MARPAT Full-text
TITLE: Preparation of (hetero)aromatic compounds for treating bone deficit conditions.

INVENTOR(S): Petrie, Charles; Orme, Mark W.; Baindur, Nand; Robbins, Kirk G.; Harris, Scott M.; Kontoyianni, Maria; Hurley, Laurence H.; Kerwin, Sean M.; Mundy, Gregory R.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Osteoscreen, Inc.; University of Texas At Austin
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9715308	A1	19970501	WO 1996-US17019	19961023
W: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2235481	A1	19970501	CA 1996-2235481	19961023
AU 9674710	A	19970515	AU 1996-74710	19961023
AU 706262	B2	19990610		
EP 866710	A1	19980930	EP 1996-936906	19961023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1201393	A	19981209	CN 1996-197827	19961023
HU 9802319	A2	19990201	HU 1998-2319	19961023
HU 9802319	A3	19991228		
BR 9611210	A	19991228	BR 1996-11210	19961023
JP 2000513324	T	20001010	JP 1997-516761	19961023
US 6008208	A	19991228	US 1997-878868	19970619
NO 9801810	A	19980622	NO 1998-1810	19980422
US 6413998	B1	20020702	US 1999-453828	19991202
PRIORITY APPLN. INFO.:			US 1995-5830P	19951023
			US 1996-735875	19961023
			WO 1996-US17019	19961023
			US 1997-878868	19970619

GI



I

AB A method for treating deficient bone growth and/or undesirable bone resorption comprises administration of compds. comprising 2 (substituted) aromatic systems spaced apart by a linker of 1.5-15 Å, is claimed. Thus, dithizone was refluxed in EtOH/HOAc for 18 h to give 25% title compound (I). In a calvarial bone growth assay, I induced a 4-fold increase in width of new calvarial bone vs. controls.

MSTR 1



G1 = OH
G2 = 83-4 81-12 80-5



G4 = N / 26



G7 = Ph (opt. substd. by 1 or more G12)
G12 = F
Patent location: claim 1

FILE 'HOME' ENTERED AT 09:35:31 ON 20 AUG 2008

SEARCH HISTORY

=> d stat que l17; d his nofile
L14 STR



VAR G1=NO2/CN/58/18
VAR G2=20/22/24
VAR G3=11/12/13
VAR G4=50/51/53
VAR G5=35/7
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 18 19 58
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE
L17 110 SEA FILE=REGISTRY SSS FUL L14

100.0% PROCESSED 47108 ITERATIONS 110 ANSWERS
SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 09:14:06 ON 20 AUG 2008)

FILE 'CAPLUS' ENTERED AT 09:14:56 ON 20 AUG 2008
E US2005-538126/APPS
L1 1 SEA ABB=ON US2005-538126/AP
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 09:15:19 ON 20 AUG 2008
L2 124 SEA ABB=ON (100-39-0/BI OR 108-24-7/BI OR 126-81-8/BI OR
13139-15-6/BI OR 13726-84-6/BI OR 13734-34-4/BI OR 13734-41-3/B
I OR 14011-37-1/BI OR 15057-43-9/BI OR 15761-38-3/BI OR
15761-39-4/BI OR 1676-90-0/BI OR 18523-22-3/BI OR 18942-49-9/BI

```
                OR 2003-10-3/BI OR 202664-36-6/BI OR 2227-64-7/BI OR 24277-39-
                2/BI OR 2483-46-7/BI OR 2488-15-5/BI OR 27475-19-0/BI OR
                30095-56-8/BI OR 34582-32-6/BI OR 4142-98-7/BI OR 4341-24-6/BI
                OR 4530-20-5/BI OR 493-72-1/BI OR 5000-65-7/BI OR 504-02-9/BI
                OR 50916-55-7/BI OR 51012-64-7/BI OR 52605-49-9/BI OR 53631-18-
                8/BI OR 598-31-2/BI OR 62-23-7/BI OR 6344-42-9/BI OR 66310-85-8
                /BI OR 67-63-0/BI OR 708983-92-0/BI OR 708983-93-1/BI OR
                708983-95-3/BI OR 708983-96-4/BI OR 708983-97-5/BI OR 708983-98
                -6/BI OR 708983-99-7/BI OR 708984-00-3/BI OR 708984-01-4/BI OR
                708984-02-5/BI OR 708984-03-6/BI OR 708984-04-7/BI OR 708984-05
                -8/BI OR 708984-06-9/BI OR 708984-07-0/BI OR 708984-08-1/BI OR
                708984-09-2/BI OR 708984-10-5/BI OR 708984-11-6/BI OR 708984-12
                -7/BI OR 708984-13-8/BI OR 708984-14-9/BI OR 708984-15-0/BI OR
                708984-16-1/BI OR 708984-17-2/BI OR 708984-18-3/BI OR 708984-19
                -4/BI OR 708984-20-7/BI OR 708984-21-8/BI OR 708984-22-9/BI OR
                708984-23-0/BI OR 708984-24-1/BI OR 708984-25-2/BI OR 708984-26
                -3/BI OR 708984-27-4/BI OR 708984-28-5/BI OR 708984-29-6/BI OR
                708984-30-9/BI OR 708984-31-0/BI OR 708984-32-1/BI OR 708984-33
                -2/BI OR 708984-34-3/BI OR 708984-35-4/BI OR 708984-36-5/BI OR
                708984-37-6/BI OR 708984-38-7/BI OR 708984-39-8/BI OR 708984-40
                -1/BI OR 708984-41-2/BI OR 708984-42-3/BI OR 708984-43-4/BI OR
                708984-44-5/BI OR 708984-45-6/BI OR 708984-46-7/BI OR 708984-47
                -8/BI OR 708984-48-9/BI OR 708984-49-0/BI OR 708984-51-4/BI OR
                708984-52-5/BI OR 708984-53-6/BI OR 708984-54-7/BI OR 708984-55
                -8/BI OR 708984-56-9/BI OR 708984-57-0/BI OR 708984-58-1/BI OR
                708984-59-2/BI OR 708984-60-5/BI OR 708984-61-6/BI OR 708984-62
                -7/BI OR 708984-63-8/BI OR 708984-64-9/BI OR 708984-65-0/BI OR
                708984-66-1/BI OR 708984-67-2/BI OR 708984-68-3/BI OR 708984-69
                -4/BI OR 708984-70-7/BI OR 708984-71-8/BI OR
L3              STR
L4           0 SEA SSS SAM L3

     FILE 'STNGUIDE' ENTERED AT 09:21:15 ON 20 AUG 2008

     FILE 'REGISTRY' ENTERED AT 09:22:54 ON 20 AUG 2008
L5              STR L3
L6           0 SEA SSS SAM L5
L7              STR L5
L8           0 SEA SSS SAM L7
L9              STR L3
L10          4 SEA SSS SAM L9
L11             STR L7
L12          3 SEA SSS SAM L11
                D SCAN
L13          3 SEA ABB=ON  L12 AND L2
L14             STR L11
L15          3 SEA SSS SAM L14
L16      47108 SEA SSS FUL L14 EXTEND
L17        110 SEA SSS FUL L14
                SAVE TEMP L17 JAI126FULL/A
L18         71 SEA ABB=ON  L17 AND L2

     FILE 'ZCAPLUS' ENTERED AT 09:33:20 ON 20 AUG 2008
L19          3 SEA ABB=ON  L17

     FILE 'MARPAT' ENTERED AT 09:33:34 ON 20 AUG 2008
L20          0 SEA SSS SAM L14
L21       6334 SEA SSS FUL L14 EXTEND
L22          9 SEA SSS FUL L14
                SAVE TEMP L22 JAI126MARP/A
```

```
     FILE 'STNGUIDE' ENTERED AT 09:34:20 ON 20 AUG 2008

     FILE 'REGISTRY' ENTERED AT 09:34:55 ON 20 AUG 2008
                D STAT QUE L17

     FILE 'ZCAPLUS' ENTERED AT 09:34:56 ON 20 AUG 2008
                D QUE NOS L19

     FILE 'MARPAT' ENTERED AT 09:34:56 ON 20 AUG 2008
                D QUE NOS L22

     FILE 'ZCAPLUS, MARPAT' ENTERED AT 09:34:56 ON 20 AUG 2008
L23           10 DUP REM L19 L22 (2 DUPLICATES REMOVED)
                     ANSWERS '1-3' FROM FILE ZCAPLUS
                     ANSWERS '4-10' FROM FILE MARPAT
                D IBIB ABS HITSTR 1-3
                D IBIB ABS QHIT 4-10

     FILE 'HOME' ENTERED AT 09:35:31 ON 20 AUG 2008
                D STAT QUE L17

=>
```